Most cancer drugs fast-tracked through a special FDA program do not appear to actually help cancer patients live longer, according to the findings of a new study.
The FDA announced new bladder cancer restrictions on the use of Keytruda and Tecentriq, following indications that they could lower survival rates for some patients.
An FDA warning indicates that Keytruda and Tecentriq may decrease the risk of survival in certain metastatic urothelial cancer patients.
The side effects of Yervoy, Keytruda and other similar cancer drugs may increase the risk of musculoskeletal problems, according to the findings of a new study.
A clinical trial testing Keytruda as a second-line treatment for gastrointestinal cancer failed after the drug showed lower survival rates than an existing drug.
After halting clinical trials involving the cancer drug Keytruda for treatment of multiple myeloma, the FDA has expanded the suspension to trials involving Opdivo, a similar medication.
Two clinical trials have been halted and the FDA is warning that Keytruda side effects may increase the risk of death when used with other drugs to treat multiple myeloma.
An investigative report finds that cancer drugs and treatments are often oversold, exaggerating their effectiveness.
